Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents


Vitae Pharmaceuticals, Inc.

Notes to Unaudited Condensed Financial Statements (Continued)

As of June 30, 2014 and December 31, 2013 and
for the Six Months Ended June 30, 2014 and 2013

2. Summary of Significant Accounting Policies and Basis of Accounting (Continued)

Deferred Offering Costs

        Deferred offering costs as of June 30, 2014, consisting of legal, accounting, and printing fees, were capitalized. The Company capitalized $1.0 million of deferred offering costs as of June 30, 2014.

Significant Accounting Policies

        The Company's significant accounting policies are disclosed in the audited financial statements for the year ended December 31, 2013 included elsewhere in this prospectus. Since the date of those financial statements, there have been no changes to the Company's significant accounting policies.

3. Net Loss Per Common Share

        The following table sets forth the computation of basic and diluted net income loss per common share for the periods indicated:

 
  Six months ended June 30,  
 
  2014   2013  

Basic and diluted net loss per common share calculation:

             

Net loss attributable to common stockholders

  $ (10,019,050 ) $ (8,723,330 )
           
           

Weighted average common shares outstanding

    13,770,634     12,697,213  
           
           

Net loss per share of common stock—basic and diluted

  $ (0.73 ) $ (0.69 )
           
           

        The following outstanding securities at June 30, 2014 and 2013 have been excluded from the computation of diluted weighted shares outstanding, as they would have been anti-dilutive:

 
  June 30,  
 
  2014   2013  

Stock options

    35,252,515     43,327,067  

Restricted stock units

    9,000,000      

Warrants

    1,045,834     1,055,810  

Convertible preferred stock

    218,309,741     218,309,741  
           

Total

    263,608,090     262,692,618  
           
           

F-39